5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

por Gang, A O, Frøsig, T M, Brimnes, M K, Lyngaa, R, Treppendahl, M B, Grønbæk, K, Dufva, I H, Straten, P thor, Hadrup, S R
Publicado 2014

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

por Seymour, J F, Kim, D W, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, J L, Mahon, F-X, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A, Giles, F J
Publicado 2014

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

por Tobiasson, M, Dybedahl, I, Holm, M S, Karimi, M, Brandefors, L, Garelius, H, Grövdal, M, Högh-Dufva, I, Grønbæk, K, Jansson, M, Marcher, C, Nilsson, L, Kittang, A O, Porwit, A, Saft, L, Möllgård, L, Hellström-Lindberg, E
Publicado 2014